Selling, General & Administrative Expenses
The latest quarterly sg&a expense is $1.12 Billion with a quarter-over-quarter change of +7.82%. Selling, General & Administrative (SG&A) expenses include all costs related to selling products and running the business that are not directly tied to production.
GEHC SG&A Expense
Reported quarterly SG&A expense; no daily interpolation.
Current SG&A Expense
$1.12B
$1.12 Billion
Quarter-over-Quarter Change
+7.82%
vs. $1.04B prior quarter
Historical Data
21
Quarters of data available
Quarterly SG&A Expense History
| Period | SG&A Expense | QoQ Change | % Change |
|---|---|---|---|
| Q1 2026 | $1.12B | +$81.00M | +7.82% |
| Q4 2025 | $1.04B | $-9.00M | -0.86% |
| Q3 2025 | $1.04B | +$16.00M | +1.55% |
| Q2 2025 | $1.03B | $-11.00M | -1.06% |
| Q1 2025 | $1.04B | $-90.00M | -7.96% |
| Q4 2024 | $1.13B | +$96.00M | +9.28% |
| Q3 2024 | $1.03B | $-33.00M | -3.09% |
| Q2 2024 | $1.07B | +$29.00M | +2.79% |
| Q1 2024 | $1.04B | $-114.00M | -9.90% |
| Q4 2023 | $1.15B | +$156.00M | +15.66% |
| Q3 2023 | $996.00M | $-76.00M | -7.09% |
| Q2 2023 | $1.07B | +$10.00M | +0.94% |
| Q1 2023 | $1.06B | +$178.00M | +20.14% |
| Q4 2022 | $884.00M | $-24.00M | -2.64% |
| Q3 2022 | $908.00M | +$0 | 0.00% |
| Q2 2022 | $908.00M | $-23.00M | -2.47% |
| Q1 2022 | $931.00M | +$21.00M | +2.31% |
| Q4 2021 | $910.00M | $-4.00M | -0.44% |
| Q3 2021 | $914.00M | +$44.50M | +5.12% |
| Q2 2021 | $869.50M | +$0 | 0.00% |
| Q1 2021 | $869.50M | — | — |
About GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Peter J. Arduini